Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 41%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insulet's revenue projections indicate a robust growth trajectory, with expectations of reaching $2.7 billion in FY25 and $4.2 billion by FY28, reflecting a compound annual growth rate (CAGR) of 16.3%. The company is raising its sales growth guidance for 2025 to 28-29% year-over-year, attributed to its strategy to increase market share in the under-penetrated diabetes market, particularly in regions such as Europe, the Middle East, and Asia. Additionally, with a gross margin improvement forecasted to exceed 71% and operating margins raised to 17.3-17.5%, Insulet is well-positioned for sustained profitability and value creation for its shareholders.

Bears say

Insulet's outlook is negatively affected by projected declines in its Drug Delivery segment, with expectations of a decrease of 85-95% year-over-year, significantly impacting overall revenue. The company's challenges in driving U.S. expansion and maintaining competitive positioning are further exacerbated by a backdrop of macroeconomic pressures, including inflation and regulatory hurdles. Additionally, risks related to product adoption, reimbursement from third-party payers, and geopolitical limitations on international expansion contribute to a cautious sentiment regarding the company's future performance.

Insulet (PODD) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 41% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 17 analysts, Insulet (PODD) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $367.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $367.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.